AbbVie releases new results for Epcoritamab in patients with relapsed/refractory diffuse large b-cell lymphoma

AbbVie has recently announced their new topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator’s choice of chemoimmunotherapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Note that EPCORE DLBCL-1 demonstrates improvement in PFS in patients with R/R DLBCL who were treated with a CD3xCD20 T-cell engaging bispecific monotherapy. The global study enrolled 483 patients with R/R DLBCL with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant.

In addition, the adverse events observed in this study appear consistent with known safety of epcoritamab. AbbVie and Genmab are working to assess the potential impact of various factors, including the COVID-19 pandemic and the increased availability of novel anti-lymphoma therapies during the study timeline. The data will be submitted for presentation at a future medical meeting, and AbbVie and Genmab will engage global regulatory authorities to determine next steps.

Additionally, Epcoritamab has received regulatory approval in certain lymphoma indications in more than 65 countries. AbbVie and Genmab remain committed to advancing epcoritamab, with ongoing clinical programs evaluating the therapy as a monotherapy and in combination regimens across treatment lines and a broad range of hematologic malignancies.

---

---

Related Topics and Keywords

AbbVie, large b cell lymphoma, lymphoma